Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARD.

Abstract

BACKGROUND:

The CARD study demonstrated superiority of cabazitaxel over abiraterone/enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) who received prior docetaxel and progressed ≤12 months on the alternative androgen-receptor-targeted agent (ARTA). The objective was to compare characteristics and treatment patterns of patients from a real-world dataset with the CARD population.

METHODS:

Real-world data were collected from Medimix Live TrackerTM, a retrospective, global oncology database of healthcare professional-reported electronic patient medical forms (2001-2019), with data from patients from Europe, USA, Brazil and Japan. The database contained patient, tumor and treatment information for 12,140 patients who received ≥1 line of treatment for mCRPC. A CARD-like cohort included patients treated with docetaxel, prior abiraterone/enzalutamide and cabazitaxel.

RESULTS:

A large proportion of patients received ≥2 lines of ARTA (35.1%) with 42% of patients who received a first-line ARTA receiving another ARTA in second line. Of the total patients, 452 were eligible for the CARD-like cohort. Median age of the CARD-like cohort was comparable to CARD (73 vs 70 years). The CARD-like cohort had unfavorable disease characteristics vs CARD: ECOG PS ≥ 2 (45% vs 4.7%); metastasis at diagnosis (46% vs 38%) and Gleason 8-10 (65% vs 57%). More patients in the CARD-like cohort received ARTA before docetaxel (48% vs 39%) and received the first ARTA for >12 months (30% vs 17%) compared with CARD. Despite more patients in the CARD-like cohort receiving the lower 20 mg/m2 dose of cabazitaxel (55% vs 21%), cabazitaxel treatment duration was similar (21.9 vs 22.0 weeks).

CONCLUSIONS:

Sequential use of ARTA was frequent. Results indicate the CARD population is reflective of routine clinical practice and duration of response to cabazitaxel was similar in a real-world population.

• Authors: Ronald de Wit, Stephen J Freedland, Stephane Oudard, Georgi Marinov, Philippe Capart, Austin J Combest, Ryan Peterson, Ayse Ozatilgan, Alicia K Morgans
• Journal: Prostate cancer and prostatic diseases (Prostate Cancer Prostatic Dis) Vol. 26 Issue 1 Pg. 67-73 (03 2023) ISSN: 1476-5608 [Electronic] England
• PMID: 35039605 (Publication Type: Randomized Controlled Trial, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2022. The Author(s).

Chemical References

• cabazitaxel
• Docetaxel
• enzalutamide
• Nitriles

Topics

• Male
• Humans
• Aged
• Docetaxel (therapeutic use)
• Prostatic Neoplasms, Castration-Resistant (drug therapy, pathology)
• Retrospective Studies
• Disease-Free Survival
• Nitriles (therapeutic use)
• Treatment Outcome
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)